632 related articles for article (PubMed ID: 3102161)
1. Evaluation of a new triphasic oral contraceptive in private practice.
Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
[TBL] [Abstract][Full Text] [Related]
2. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
[TBL] [Abstract][Full Text] [Related]
3. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
4. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
5. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
[TBL] [Abstract][Full Text] [Related]
6. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
Anderson FD
Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
[TBL] [Abstract][Full Text] [Related]
7. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
8. A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.
Masson S; Franssen E; Hilditch JR; Powell MG
Contraception; 1993 Jan; 47(1):43-54. PubMed ID: 8436001
[TBL] [Abstract][Full Text] [Related]
9. Two oral contraceptives, efficacy, serum proteins, and lipid metabolism. A comparative multicentre study on a triphasic and a fixed dose combination.
Cullberg G; Samsioe G; Andersen RF; Bredesgaard P; Andersen NB; Ernerot H; Fanøe E; Fylling P; Haack-Sørensen PE; Klottrup P; Pedersen JH; Sandager T
Contraception; 1982 Sep; 26(3):229-43. PubMed ID: 6217028
[TBL] [Abstract][Full Text] [Related]
10. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
11. The short-term effects of a low-dose oral contraceptive on glucose metabolism, plasma lipids and blood clotting factors.
Skouby SO; Wagner HH; Andersen O
Contraception; 1983 Nov; 28(5):489-99. PubMed ID: 6425010
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism.
Loke DF; Ng CS; Samsioe G; Holck S; Ratnam SS
Contraception; 1990 Nov; 42(5):535-54. PubMed ID: 2125546
[TBL] [Abstract][Full Text] [Related]
13. Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months.
Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
Contraception; 1988 Jul; 38(1):27-35. PubMed ID: 3139358
[TBL] [Abstract][Full Text] [Related]
14. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
15. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
Janaud A; Rouffy J; Upmalis D; Dain MP
Acta Obstet Gynecol Scand Suppl; 1992; 156():33-8. PubMed ID: 1324555
[TBL] [Abstract][Full Text] [Related]
16. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version.
Carlborg L
Contraception; 1983 May; 27(5):439-52. PubMed ID: 6349925
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with a triphasic oral contraceptive ('Trinordiol') in young women.
Gaspard UJ; Deville JL; Dubois M
Curr Med Res Opin; 1983; 8(6):395-404. PubMed ID: 6406157
[TBL] [Abstract][Full Text] [Related]
18. Five-year, multicenter study of a triphasic, low-dose, combination oral contraceptive.
Woutersz TB; Korba VD
Int J Fertil; 1988; 33(6):406-10. PubMed ID: 2906915
[TBL] [Abstract][Full Text] [Related]
19. Lipid and biochemical changes after low-dose oral contraception.
Loke DF; Ng CS; Holck S; Hall PE; Ratnam SS
Contraception; 1992 Sep; 46(3):227-41. PubMed ID: 1451519
[TBL] [Abstract][Full Text] [Related]
20. The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.
Spellacy WN; Ellingson AB; Tsibris JC
Fertil Steril; 1989 Jan; 51(1):71-4. PubMed ID: 2642814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
